Effect of antiretroviral agents on T-lymphocyte subset counts in healthy HIV-negative individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 5, 2000, Pages 440-443

  Puro, Vincenzo ^a   Ippolito, Giuseppe ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral agents; CD4 T lymphocytes; HIV; Postexposure prophylaxis

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; INDINAVIR; LAMIVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

APOPTOSIS; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; DRUG EFFECT; HEALTH CARE PERSONNEL; IMMUNOLOGY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; OCCUPATIONAL DISEASE; RETROSPECTIVE STUDY; SERODIAGNOSIS; T LYMPHOCYTE SUBPOPULATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEALTH PERSONNEL; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MALE; OCCUPATIONAL DISEASES; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; ZIDOVUDINE;

EID: 0034662740     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200008150-00007     Document Type: Article

References (9)

1. + cell counts, and HIV-1 production by cells
2. + lymphocyte count variations in HIV-negative subjects treated with zidovudine
3. Do nucleoside analogues directly influence T-lymphocyte subset counts? The pediatric model
4. + cell count in HIV-uninfected individuals
5. + lymphocyte responses to antiretroviral therapy of HIV infection
6. Surveillance of occupational exposure to bloodborne pathogens in health care workers: The Italian national programme
7. Public Health Service guidelines for the management of health care worker exposures to HIV and recommendations for post exposure prophylaxis
8. + T-cell determinations in persons with human immunodeficiency virus infection